301201.SZ
Chengda Pharmaceuticals Co., Ltd.
SZSE · C 制造业 · CN
CNY 23.79
−0.92%Year over year
Reported trailing growth
- Revenue
- +48.5%
- EBITDA
- —
- EBIT
- +107.0%
- EPS
- +92.7%
- Free cash flow
- +95.8%
- Operating cash flow
- +240.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -0.4%
- EBITDA
- -20.2%
- EBIT
- +68.1%
- Net income
- +57.6%
- EPS
- +57.4%
- Free cash flow
- +86.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026